AHR Agonists Market Trends Signal Promising Growth in Immunology and Dermatology Therapeutics | DelveInsight [Yahoo! Finance]
Organon & Co. (OGN)
Company Research
Source: Yahoo! Finance
The approval of VTAMA for treating both plaque psoriasis and atopic dermatitis has confirmed the therapeutic potential of AHR modulation, establishing it as a novel, non-steroidal treatment option in dermatology. Additionally, the launch of emerging therapies such as AT193, AQ312, DMVT-506, AT177, and others will further fuel the AHR agonist market. LAS VEGAS Oct. 7, 2025 /PRNewswire/ -- DelveInsight's AHR Agonists Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Ulcerative Colitis, Atopic Dermatitis, Plaque Psoriasis, Hidradenitis Suppurativa, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging AHR agonists, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented in
Show less
Read more
Impact Snapshot
Event Time:
OGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OGN alerts
High impacting Organon & Co. news events
Weekly update
A roundup of the hottest topics
OGN
News
- Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know [Yahoo! Finance]Yahoo! Finance
- Organon To Present at the Piper Sandler 37th Annual Healthcare ConferenceBusiness Wire
- Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the USPR Newswire
- Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the USBusiness Wire
- Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGNBusiness Wire
OGN
Earnings
- 11/10/25 - Beat
OGN
Sec Filings
- 11/17/25 - Form 4
- 11/17/25 - Form 4
- 11/12/25 - Form 4
- OGN's page on the SEC website